# Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs

> **NCT07303556** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Nazarbayev University** · enrollment: 120 (estimated)

## Conditions studied

- Heart Failure
- Diabete Type 2
- Arterial Hypertension

## Interventions

- **DRUG:** Tirzepatide (Mounjaro)
- **DRUG:** dapagliflozin, empagliflozin, metformin

## Key facts

- **NCT ID:** NCT07303556
- **Lead sponsor:** Nazarbayev University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-18
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07303556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07303556, "Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07303556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*